Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
AssigneesRegeneron Pharmaceuticals, Inc., Sanofi Biotechnology
InventorsJennifer D. Hamilton, Meagan P. O′Brien, Allen Radin, Marcella Ruddy, Heribert Staudinger
Life of this patent
Estimating the term…
Abstract
Methods for enhancing the efficacy, safety, and/or tolerability of a grass allergen-specific subcutaneous immunotherapy (SCIT) regimen in a subject having a grass allergy are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.
Claims18
A method for enhancing the tolerability of a grass allergen-specific immunotherapy in a subject having an allergy to a grass allergen, the method comprising:
- administering to the subject one or more doses of an interleukin-4 receptor (IL-4R) antagonist in combination with a grass allergen-specific immunotherapy regimen, wherein the IL-4R antagonist is subcutaneously administered and wherein at least one dose of the IL-4R antagonist is administered prior to the start of the grass allergen-specific immunotherapy regimen;
- wherein the IL-4R antagonist is dupilumab.
Dependencies are inferred from the claim text.